Here are the 10-K annual reports from Biotricity Inc (BTCY) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow BTCY and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BTCY filings page.
Biotricity Inc. is a Nevada-based medical technology company focused on remote biometric monitoring, particularly cardiac diagnostics and chronic care. Key offerings include FDA-cleared Bioflux mobile cardiac outpatient monitoring, Biocore and cellular Biocore Pro devices, plus consumer Bioheart monitors, the Biocare chronic-care platform and Biokit remote patient monitoring kits.
The company pursues an insourced, technology-as-a-service model, earning utilization-based recurring fees from cardiology offices, hospitals and IDTFs. It is expanding U.S. sales coverage and developing AI-driven cardiac analytics on major cloud platforms, while continuing to seek additional FDA clearances. Biotricity remains unprofitable, reporting an accumulated deficit of $142,570,243, and supports operations with a secured credit facility with borrowings of $14,45 million maturing in 2026 alongside ongoing R&D investment.